Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 1, Issue 26
December 12 2017
Issue Cover

Table of Contents

BLOOD ADVANCES TALK

Catalyzing innovation in clinical trial design and analysis at NHLBI: a funding opportunity for clinical trials in blood disorders
Clinical Trials & Observations
Donna M. DiMichele
View Articletitled, Catalyzing innovation in clinical trial design and analysis at NHLBI: a funding opportunity for clinical trials in blood disorders
Supplemental data

POINT-COUNTERPOINT

The case for HLA-identical sibling hematopoietic stem cell transplantation in children with symptomatic sickle cell anemia
Courtney D. Fitzhugh,Mark C. Walters

This article has a companion Counterpoint by DeBaun and Clayton.

View Articletitled, The case for HLA-identical sibling hematopoietic stem cell transplantation in children with symptomatic sickle cell anemia
Primum non nocere: the case against transplant for children with sickle cell anemia without progressive end-organ disease
Michael R. DeBaun,Ellen Wright Clayton

This article has a companion Point by Fitzhugh and Walters.

View Articletitled, Primum non nocere: the case against transplant for children with sickle cell anemia without progressive end-organ disease

DRUG ADVANCES

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma
Reid W. Merryman,Philippe Armand,Kyle T. Wright,Scott J. Rodig
View Articletitled, Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma

REVIEW ARTICLES

Aging, hematopoiesis, and the myelodysplastic syndromes
Stephen S. Chung,Christopher Y. Park
View Articletitled, Aging, hematopoiesis, and the myelodysplastic syndromes
Developing T-cell therapies for lymphoma without receptor engineering
Melanie Grant,Catherine M. Bollard
View Articletitled, Developing T-cell therapies for lymphoma without receptor engineering
Hemophilia gene therapy comes of age
Lindsey A. George
View Articletitled, Hemophilia gene therapy comes of age

CLINICAL TRIALS AND OBSERVATIONS

Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH
Clinical Trials & Observations
Anna Hayden,Molly Lin,Sujin Park,Morris Pudek,Marion Schneider,Michael B. Jordan,Andre Mattman,Luke Y. C. Chen
View Articletitled, Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH
Supplemental data
Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants
Clinical Trials & Observations
Jordan K. Schaefer,Suman L. Sood,Brian Haymart,Xiaokui Gu,Xiaowen Kong,Eva Kline-Rogers,Steven Almany,Jay Kozlowski,Gregory D. Krol,Scott Kaatz,James B. Froehlich,Geoffrey D. Barnes
View Articletitled, Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants

HEMATOPOIESIS AND STEM CELLS

Osteomacs interact with megakaryocytes and osteoblasts to regulate murine hematopoietic stem cell function
Safa F. Mohamad,Linlin Xu,Joydeep Ghosh,Paul J. Childress,Irushi Abeysekera,Evan R. Himes,Hao Wu,Marta B. Alvarez,Korbin M. Davis,Alexandra Aguilar-Perez,Jung Min Hong,Angela Bruzzaniti,Melissa A. Kacena,Edward F. Srour
View Articletitled, Osteomacs interact with megakaryocytes and osteoblasts to regulate murine hematopoietic stem cell function
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Regulation of the maturation of human monocytes into immunosuppressive macrophages
Defne Bayik,Debra Tross,Lydia A. Haile,Daniela Verthelyi,Dennis M. Klinman
View Articletitled, Regulation of the maturation of human monocytes into immunosuppressive macrophages
Supplemental data
TLR2 agonism reverses chemotherapy-induced neutropenia in Macaca fascicularis
Nicholas J. Laping,Michael P. DeMartino,Joshua E. Cottom,Jeffrey M. Axten,John G. Emery,Jeffrey H. Guss,Miriam Burman,James J. Foley,Mui Cheung,Allen Oliff,Sanjay Kumar
View Articletitled, TLR2 agonism reverses chemotherapy-induced neutropenia in <em>Macaca fascicularis</em>

LYMPHOID NEOPLASIA

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL
Clinical Trials & Observations
Monika Pilichowska,Stefania Pittaluga,Judith A. Ferry,Jessica Hemminger,Hong Chang,Jennifer A. Kanakry,Laurie H. Sehn,Tatyana Feldman,Jeremy S. Abramson,Athena Kritharis,Francisco J. Hernandez-Ilizaliturri,Izidore S. Lossos,Oliver W. Press,Timothy S. Fenske,Jonathan W. Friedberg,Julie M. Vose,Kristie A. Blum,Deepa Jagadeesh,Bruce Woda,Gaurav K. Gupta,Randy D. Gascoyne,Elaine S. Jaffe,Andrew M. Evens
View Articletitled, Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL
Supplemental data
Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib
Clinical Trials & Observations
Alexander P. Bye,Amanda J. Unsworth,Michael J. Desborough,Catherine A. T. Hildyard,Niamh Appleby,David Bruce,Neline Kriek,Sophie H. Nock,Tanya Sage,Craig E. Hughes,Jonathan M. Gibbins
View Articletitled, Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib
Supplemental data

MYELOID NEOPLASIA

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy
Clinical Trials & Observations
Zimu Gong,L. Jeffrey Medeiros,Jorge E. Cortes,Zi Chen,Lan Zheng,Yan Li,Shi Bai,Pei Lin,Roberto N. Miranda,Jeffrey L. Jorgensen,Timothy J. McDonnell,Wei Wang,Hagop M. Kantarjian,Shimin Hu
View Articletitled, Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Low fetal hemoglobin percentage is associated with silent brain lesions in adults with homozygous sickle cell disease
Clinical Trials & Observations
David Calvet,Titien Tuilier,Nicolas Mélé,Guillaume Turc,Anoosha Habibi,Nassim Ait Abdallah,Loubna Majhadi,François Hemery,Myriam Edjlali,Frédéric Galacteros,Pablo Bartolucci
View Articletitled, Low fetal hemoglobin percentage is associated with silent brain lesions in adults with homozygous sickle cell disease
Erythrocyte β spectrin can be genetically targeted to protect mice from malaria
Patrick M. Lelliott,Hong Ming Huang,Matthew W. Dixon,Arman Namvar,Adam J. Blanch,Vijay Rajagopal,Leann Tilley,Cevayir Coban,Brendan J. McMorran,Simon J. Foote,Gaetan Burgio
View Articletitled, Erythrocyte β spectrin can be genetically targeted to protect mice from malaria
Supplemental data

THROMBOSIS AND HEMOSTASIS

Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data
Clinical Trials & Observations
Matteo Rota,Paolo A. Cortesi,Roberto Crea,Alessandro Gringeri,Lorenzo G. Mantovani
View Articletitled, Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data

VASCULAR BIOLOGY

DNA and factor VII–activating protease protect against the cytotoxicity of histones
Gerben Marsman,Helen von Richthofen,Ingrid Bulder,Florea Lupu,Jan Hazelzet,Brenda M. Luken,Sacha Zeerleder
View Articletitled, DNA and factor VII–activating protease protect against the cytotoxicity of histones
Supplemental data

ERRATUM

Aldenhoven M, van den Broek BTA, Wynn RF, et al. Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation. Blood Adv. 2017;1(24):2236-2242.
View Articletitled, Aldenhoven M, van den Broek BTA, Wynn RF, et al. Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation. <em>Blood Adv.</em> 2017;1(24):2236-2242.
  • Cover Image

    Cover Image

    issue cover

    COVER FIGURE
    Genes and regulatory networks activated when human monocytes are stimulated with PAM3 (blue) or macrophage colony-stimulating factor (red) to become suppressive macrophages. See the article by Bayik et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

Time to revisit reduced-dose radiotherapy for PCNSL?
Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.
Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals